High mobility group box protein-1 in HIV-1 infection: Connecting microbial translocation, cell death and immune activation

Current HIV Research

Volumn 9, Issue 1, 2011, Pages 6-10

  Troseid, Marius ^a   Sönnerborg, Anders ^b   Nowak, Piotr ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HIV 1; HMGB 1; Immune activation; Microbial translocation; Necrosis; Toll like receptor

Indexed keywords

ALARMIN; CELL PROTEIN; DNA; HIGH MOBILITY GROUP B1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL TRANSLOCATION; BACTERIUM; CELL DEATH; CELL TYPE; DNA BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOREACTIVITY; NONHUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; REGENERATION; VIROTHERAPY; VIRUS ENTRY; VIRUS REPLICATION;

EID: 79951734457     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016211794582632     Document Type: Article

References (59)

1. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309(8): 453-8.
2. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95(1): 249-55.
3. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5(1): 83-9.
4. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997; 187-228.
5. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179(4): 859-70.
6. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1(1): 23-30.
7. Olsson J, Poles M, Spetz AL, et al. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and betachemokines. J Infect Dis 2000; 182(6): 1625-35.
8. McGowan I, Elliott J, Fuerst M, et al. Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J Acquir Immune Defic Syndr 2004; 37(2): 1228-36.
9. Clayton F, Reka S, Cronin WJ, Torlakovic E, Sigal SH, Kotler DP. Rectal mucosal pathology varies with human immunodeficiency virus antigen content and disease stage. Gastroenterology 1992; 103(3): 919-33.
10. Kotler DP, Reka S, Clayton F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. Dig Dis Sci 1993; 38(6): 1119-27.
11. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12(12): 1365-71.
12. Gregson JN, Steel A, Bower M, Gazzard BG, Gotch FM, Goodier MR. Elevated plasma lipopolysaccharide is not sufficient to drive natural killer cell activation in HIV-1-infected individuals. AIDS 2009; 23(1): 29-34.
13. Goodwin GH, Sanders C, Johns EW. A new group of chromatinassociated proteins with a high content of acidic and basic amino acids. Eur J Biochem 1973; 38(1): 14-9.
14. Ferrari S, Finelli P, Rocchi M, Bianchi ME. The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics 1996; 35(2): 367-71.
15. Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 2005; 15(5): 496-506.
16. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009; 86(3): 573-6.
17. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006; 17(3): 189-201.
18. Agresti A, Lupo R, Bianchi ME, Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003 7; 302(2): 421-6.
19. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5(4): 331-42.
20. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010; 1799(1-2): 101-13.
21. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418(6894): 191-5.
22. Bell CW, Jiang W, Reich CF, III, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291(6): C1318-C1325.
23. Urbonaviciute V, Furnrohr BG, Meister S, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205(13): 3007-18.
24. Banerjee S, Friggeri A, Liu G, Abraham E. The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J Leukoc Biol 2010; 88: 973-9.
25. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81(1): 1-5.
26. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 2006; 7(8): 774-8.
27. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285(5425): 248-51.
28. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192(4): 565-70.
29. Palumbo R, Sampaolesi M, De MF, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164(3): 441-9.
30. Limana F, Germani A, Zacheo A, et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res 2005; 97(8): e73-e83.
31. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NFkappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274(28): 19919-24.
32. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007; 81(1): 49-58.
33. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008; 180(7): 5067-74.
34. Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110(6): 1970-81.
35. Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8(5): 487-96.
36. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008; 180(4): 2531-7.
37. Wang H, Ward MF, Fan XG, Sama AE, Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006; 19(1): 3-9.
38. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 2010; 1799(1-2): 141-8.
39. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
40. Yasuda T, Ueda T, Takeyama Y, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006; 33(4): 359-63.
41. Zhang S, Zhong J, Yang P, Gong F, Wang CY. HMGB1, an innate alarmin, in the pathogenesis of type 1 diabetes. Int J Clin Exp Pathol 2009; 3(1): 24-38.
42. Barqasho B, Nowak P, Abdurahman S, Walther-Jallow L, Sonnerborg A. Implications on the release of HMGB1 from dying cells during HIV-1 infection in vitro. J Gen Virol 2010; 91(Pt 7): 1800-9.
43. Nowak P, Barqasho B, Treutiger CJ, et al. HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. Cytokine 2006; 34(1-2): 17-23.
44. Saidi H, Melki MT, Gougeon ML. HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk. PLoS One 2008; 3(10): e3601.
45. Thierry S, Gozlan J, Jaulmes A, Boniface R, et al. High-mobility group box 1 protein induces HIV-1 expression from persistently infected cells. AIDS 2007; 21(3): 283-92.
46. Cassetta L, Fortunato O, Adduce L, et al. Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines. AIDS 2009; 23(5): 567-77.
47. Naghavi MH, Nowak P, Andersson J, et al. Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. Virology 2003; 314(1): 179-89.
48. Arimondo PB, Gelus N, Hamy F, Payet D, Travers A, Bailly C. The chromosomal protein HMG-D binds to the TAR and RBE RNA of HIV-1. FEBS Lett 2000; 485(1): 47-52.
49. Melki MT, Saidi H, Dufour A, Olivo-Marin JC, Gougeon ML. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1. PLoS Pathog 2010; 6(4): e1000862.
50. Hindmarsh P, Ridky T, Reeves R, Andrake M, Skalka AM, Leis J. HMG protein family members stimulate human immunodeficiency virus type 1 and avian sarcoma virus concerted DNA integration in vitro. J Virol 1999; 73(4): 2994-3003.
51. Lindkvist A, Nowak P, Troseid M, Abdurahman S, Nystrom J, Sonnerborg A. HMGB1 and bacterial products synergistically induce HIV-1 replication in vitro. 17th Conference on retroviruses and opportunistic infections, San Fransisco, CA 2010; Abstract No 245.
52. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60: 471-84.
53. Nowak P, Barqasho B, Sonnerborg A. Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. AIDS 2007; 21(7): 869-71.
54. Carrol ED, Mankhambo LA, Jeffers G, et al. The diagnostic and prognostic accuracy of five markers of serious bacterial infection in Malawian children with signs of severe infection. PLoS One 2009; 4(8): e6621.
55. Troseid M, Nowak P, Nystrom J, Lindkvist A, Abdurahman S, Sonnerborg A. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. AIDS 2010; 24(11): 1733-7
56. Pine SO, McElrath MJ, Bochud PY. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 2009; 23(18): 2387-95.
57. Muthumani G, Laddy DJ, Sundaram SG, et al. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, highmobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology 2009; 128(1 Suppl): e612-e620.
58. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007; 81(1): 100-7.
59. Mantell LL, Parrish WR, Ulloa L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 2006; 25(1): 4-11.